Acetylon Pharma Raises $12.4M
Acetylon Pharmaceuticals, a developer of drugs that inhibit HDAC enzymes to treat cancer and autoimmune diseases, has raised $12.4 million of a proposed $30 million second round of equity financing, according to an SEC filing. The Boston startup, which is developing technology based on discoveries made by researchers at the Dana-Farber Cancer Institute and Harvard University, had previously raised $9.25 million in a Series A financing. Walter Ogier, the firm’s chief executive, told me in an August 2009 interview that one of his backers was the Kraft Group, the company that owns the New England Patriots. The firm has not disclosed its other investors.